12/26
04:57 pm
nrsn
NeuroSense Therapeutics files to sell 5.28M ordinary shares for holders [Seeking Alpha]
Low
Report
NeuroSense Therapeutics files to sell 5.28M ordinary shares for holders [Seeking Alpha]
12/23
09:17 am
nrsn
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS [Yahoo! Finance]
Medium
Report
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS [Yahoo! Finance]
12/23
09:00 am
nrsn
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
High
Report
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
12/18
10:43 am
nrsn
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results [Yahoo! Finance]
12/18
10:25 am
nrsn
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
Low
Report
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
12/16
10:49 am
nrsn
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) had its "hold" rating re-affirmed by analysts at Maxim Group.
Medium
Report
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) had its "hold" rating re-affirmed by analysts at Maxim Group.
12/11
09:30 am
nrsn
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC [Yahoo! Finance]
Medium
Report
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC [Yahoo! Finance]
12/11
09:25 am
nrsn
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
High
Report
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
12/4
08:44 am
nrsn
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS [Yahoo! Finance]
Medium
Report
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS [Yahoo! Finance]
12/4
08:30 am
nrsn
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
Low
Report
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
12/2
08:46 am
nrsn
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price [Yahoo! Finance]
Low
Report
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price [Yahoo! Finance]
12/2
08:30 am
nrsn
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
High
Report
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
11/21
09:26 am
nrsn
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND [Yahoo! Finance]
Medium
Report
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND [Yahoo! Finance]
11/21
09:20 am
nrsn
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
Medium
Report
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
10/28
08:30 am
nrsn
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Medium
Report
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
10/28
08:01 am
nrsn
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission [Yahoo! Finance]
Low
Report
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission [Yahoo! Finance]
10/24
08:30 am
nrsn
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
Medium
Report
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
10/15
09:15 am
nrsn
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
High
Report
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
10/9
09:00 am
nrsn
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
Medium
Report
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
10/7
09:00 am
nrsn
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
Low
Report
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting